Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease | MicrobiomeTrials← Back to trialsNCT07686770
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-11-01Est. Completion: 2027-09-01
Enrollment target: 90 participants Locations- Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
- Children's Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in
Non-small Cell Lung Cancer
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United StatesEst. completion Jan 24, 2028
Non-small Cell Lung Cancer
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non…
Birmingham, United StatesEst. completion Dec 7, 2029
This is a multicenter, open-label, randomized, controlled, interventional trial followed by a long-term observational ex…
Multiple LocationsCompleted Apr 1, 2026